

2026 Taipei International Breast Cancer Symposium Oral Presentation			
Room 701A, Taipei Nangang Exhibition Center, Hall 2			Sat., September 19, 2026
Time	#	Topic	Presenter
10:30-10:40	1	CDH1-Loss Driven Unfolded Protein Response (UPR) Suppression and Transcriptomic-Proteomic Discordance in mTOR-AKT Axis Define Therapeutic Vulnerabilities in Invasive Lobular Carcinoma	Wen-Ying Lin
10:40-10:50	2	Pre-treatment tumor microenvironment profiling identifies resting mast cells as a predictor of resistance to neoadjuvant pembrolizumab-based therapy in triple-negative breast cancer	Chi-Cheng Huang
10:50-11:00	3	Proportion of Endocrine Insensitivity After CDK4/6 Inhibitors Across Endocrine Therapy Based Regimens: A Secondary Analysis Using Reconstructed Individual Patient Data	Shang-Hsuan Peng
11:00-11:10	4	Impact of Undertreatment on Survival in Elderly Breast Cancer: A Nationwide Population-Based Cohort	Jun-Hee Lee
11:10-11:20	5	Comparative Genomic Profiling of Circulating Tumor DNA and Tissue DNA Reveals Complementary Genomic Information in Japanese Patients with Metastatic Breast Cancer	Yuri Fujimoto
11:20-11:30	6	PG2-Associated Immune Priming Enhances Checkpoint Inhibitor Activity: Integrated Clinical Absolute Lymphocyte Count Dynamics and Preclinical Validation in Breast Cancer Models	Ming-Shen Dai
11:30-11:40	7	Residual ductal carcinoma in situ and axillary nodal disease after neoadjuvant chemotherapy: a subtype-specific analysis in human epidermal growth factor receptor 2-positive and triple-negative breast cancer	Chihoon Lee
11:40-11:50	8	Clinicopathologic characteristics of Asian American breast cancer patients by ethnic and geographic subgroup: A 12-year single-institution experience	Andrew Seto
11:50-12:00	9	Carry-Over Effect of Immune Checkpoint Inhibitors on Overall Survival in Patients with Advanced Cancers: A Systematic Review and Meta-Regression Analysis	Shang-Hsuan Peng
12:00-12:10	10	Validation of the ASTRRA-derived Composite Risk Model for Ovarian Function Suppression Benefit in Premenopausal HR-Positive Breast Cancer	Dahn Byun
12:10-13:10		Lunch Time	
13:10-13:20	11	False Estradiol Elevation During Abemaciclib Therapy: Clinical and Ex Vivo Evidence of Platform-Specific Immunoassay Interference	Hsing-Wu Chen
13:20-13:30	12	SGLT2 inhibitors and risk of distant metastasis in breast cancer patients with type 2 diabetes: a target trial emulation with biological plausibility analysis	Cho-Hao Lee
13:30-13:40	13	SHMT2 Couples One-Carbon Metabolism to Redox Homeostasis to Drive Triple Negative Breast Cancer (TNBC) Metastasis	Yen-Dun Tzeng
13:40-13:50	14	Trends of Breast Cancer Incidence, and Mortality by County-Level Income Disparities from 2000 to 2021	Min Kyoon Kim
13:50-14:00	15	Sole Intraoperative Radiotherapy (IORT) versus External Beam Radiotherapy (EBRT) for Early-Stage Breast Cancer: A Nationwide Cohort Study Using the Taiwan National Health Insurance Research Database	Yu-Chen Hsu
14:00-14:10	16	Pharmacogenomic Repurposing of Cardiac Glycosides Against the ATP Synthasome in Metastatic Breast Cancer	Chia-Jung Li
14:10-14:20	17	Next Generation Estrogen Receptor Degradable in Patients with Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) Metastatic Breast Cancer with Endocrine Resistance: A Systematic Review, and Meta-Analysis	Tzu-Tung Kan
14:20-14:30	18	A propensity score-adjusted real-world comparison of CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer: A Taiwanese multicenter cohort study	Tsung-Han Wu
14:30-14:40	19	Characteristics of the Tumor Immune Microenvironment in Residual Triple-Negative Breast Cancer After Neoadjuvant Therapy	Yumiko Akita
14:40-15:00		Coffee Break	
15:00-15:10	20	Revisiting adjuvant chemotherapy in premenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: real-world evidence from an Asian cohort	Jen-Yu Chuang
15:10-15:20	21	Minnelide Reprograms Multidrug-Resistant Breast Cancer Through the miR-6838- 5p/CARMA3/Ferroptosis Defense Axis	Tung-Wei Hsu
15:20-15:30	22	Real-world efficacy and safety of TS-1 plus endocrine therapy in hormone receptor-positive, HER2- negative early-stage breast cancer: A multicenter Taiwanese experience including NATALEE-eligible population.	Ching-Ting Wei
15:30-15:40	23	ILCness unmasks hidden lobular-like states within ductal breast cancer	Masanori Oshi
15:40-15:50	24	Luteolin-7-O-glucoside suppresses hormone receptor-positive breast cancer progression and metastasis through the K63-linked polyubiquitinated USP7–H3K56ac–PLK1 axis	Joseph Lin
15:50-16:00	25	Current Status of Breast Reconstruction After Mastectomy and the Risk of Postoperative Complications by Timing of Reconstruction: A Nationwide Population-Based Cohort Study in Korea	So-Youn Jung